CME

Faculty: Kevin Alexander, MD

This brief clinical discussion examines findings presented at the ESC Heart Failure 2025 meeting in Belgrade, Serbia, on the impact of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM). The analysis highlights a reduction in atrial fibrillation events and an improvement in cardiovascular outcomes among patients treated with acoramidis, including those with both wild-type and variant transthyretin (TTR). Data from the ATTRibute-CM study are reviewed, showing associations between treatment and increased serum TTR levels, delayed time to first cardiovascular hospitalization, reduced NT-proBNP levels, and lower all-cause mortality. These results suggest a clinically meaningful benefit of acoramidis and support its potential role in managing ATTR-CM.

Host: Aristides Maniatis, MD

Guest: Kari Hosack

Guest: Meagan Broeckert

Guest: Sam Watson

Join Dr. Aristides Maniatis for this Patient-Clinician Connection, a case-based activity that explores the full spectrum of care in Growth Hormone Deficiency. Through real patient and caregiver dialogues, this program teaches clinicians how to identify early signs of GHD, make accurate diagnoses, navigate pediatric-to-adult care transitions, and manage the switch from daily to long-acting growth hormone therapy. Grounded in real-life experiences and expert insights, this activity delivers practical strategies for fostering patient-centered care and improving outcomes across every stage of the GHD journey

Host: Stephen Brunton, MD, FAAFP, CDCES

Guest: John Buse, MD, PhD

Guest: Jennifer Goldman, PharmD, CDCES, BC-ADM-FCCP

Guest: Eden Miller, DO, D-ACD, D-ABOM

The diagnosis of hypercortisolism is often delayed or missed, especially in primary care settings, leading to detrimental consequences for patients, such as unnecessary morbidity and mortality. Recent data suggest that the prevalence of hypercortisolism is far higher than previously estimated. Clinicians need to be aware of optimal approaches for identifying, diagnosing, and treating hypercortisolism. New data are emerging for hypercortisolism treatments that can improve outcomes in patients with hypercortisolism and hard-to-control type 2 diabetes.

Guest: Heather Wakelee, MD, FASCO

Perioperative immunotherapy has evolved into a novel therapeutic strategy for early-stage, resectable NSCLC, maximizing the efficacy of immunotherapy when the primary tumor is still present with a high neoantigen burden. Perioperative immunotherapy also allows the use of preoperative pathology as a guide for postoperative care and offers a pathway to potential surgical intervention due to tumor shrinkage for those who are not initially eligible for surgery. Clarifying the rationale behind perioperative immunotherapy in this context is crucial for optimizing treatment strategies and outcomes.

Host: Stephen Liu, MD

Guest: Joshua K. Sabari, MD

Guest: Susan Scott, MD

The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).

Guest: Paolo A. Ascierto, MD

Guest: Hussein Tawbi, MD, PhD

This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCN Guideline® recommendations.

*This program was published on July 31st, 2025 and the information therein was up-to-date when created.

Guest: John M. Kirkwood, MD

Guest: Sapna Patel, MD

This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCN Guideline® recommendations.

*This program was published on July 31st, 2025 and the information therein was up-to-date when created.

Host: Stephen Liu, MD

Guest: Joshua K. Sabari, MD

Guest: Susan Scott, MD

The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).

Host: Stephen Liu, MD

Guest: Joshua K. Sabari, MD

Guest: Susan Scott, MD

The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).

Guest: Paolo A. Ascierto, MD

This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCN Guideline® recommendations.

*This program was published on July 31st, 2025 and the information therein was up-to-date when created.